☰

Shahin Akhondzadeh - Publications

Affiliations: 
Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran 
Area:
schizophrenia, Purinergic Receptors
Tree Info Grants Similar researchers PubMed Report error

229 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Tilaki EH, Hasanzadeh A, Shalbafan M, Moghaddam HS, Shamabadi A, Boroon M, Akhondzadeh S. Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial. Clinical Neuropharmacology. 46: 175-180. PMID 37747999 DOI: 10.1097/WNF.0000000000000564  0.31
2023 Tilaki EH, Hasanzadeh A, Shalbafan M, Moghaddam HS, Shamabadi A, Boroon M, Akhondzadeh S. Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial. Clinical Neuropharmacology. 46: 175-180. PMID 37747999 DOI: 10.1097/WNF.0000000000000564  0.31
2023 Ansari S, Sanjari Moghaddam H, Basti FA, Salehi M, Akhondzadeh S. Efficacy and safety of celecoxib monotherapy for treatment of moderate depressive symptoms following COVID-19 infection: A randomized, double-blind, placebo-controlled trial. Journal of Psychosomatic Research. 174: 111471. PMID 37660680 DOI: 10.1016/j.jpsychores.2023.111471  0.332
2023 Nasiri M, Parmoon Z, Farahmand Y, Moradi A, Farahmand K, Moradi K, Basti FA, Mohammadi MR, Akhondzadeh S. l-carnitine adjunct to risperidone for treatment of autism spectrum disorder-associated behaviors: a randomized, double-blind clinical trial. International Clinical Psychopharmacology. PMID 37551601 DOI: 10.1097/YIC.0000000000000496  0.34
2023 Nematizadeh M, Ghorbanzadeh H, Moghaddam HS, Shalbafan M, Boroon M, Keshavarz-Akhlaghi AA, Akhondzadeh S. L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial. Psychiatry and Clinical Neurosciences. PMID 37169515 DOI: 10.1111/pcn.13565  0.33
2023 Shamabadi A, Kafi F, Arab Bafrani M, Asadigandomani H, A Basti F, Akhondzadeh S. l-theanine adjunct to sertraline for major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial. Journal of Affective Disorders. 333: 38-43. PMID 37084960 DOI: 10.1016/j.jad.2023.04.029  0.346
2022 Shamabadi A, Ahmadzade A, Aqamolaei A, Mortazavi SH, Hasanzadeh A, Akhondzadeh S. Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials. Iranian Journal of Psychiatry. 17: 320-340. PMID 36474699 DOI: 10.18502/ijps.v17i3.9733  0.334
2022 Ebrahimi P, Seyedmirzaei H, Moradi K, Bagheri S, Moeini M, Mohammadi MR, Akhondzadeh S. Cilostazol as adjunctive therapy in treatment of children with autism spectrum disorders: a double-blind and placebo-controlled randomized trial. International Clinical Psychopharmacology. PMID 36165508 DOI: 10.1097/YIC.0000000000000431  0.355
2022 Abbasian F, Bagheri S, Moradi K, Keykhaei M, Etemadi A, Shalbafan M, Shariati B, Vaseghi S, Samsami FS, Akhondzadeh S. Evidence for Anti-inflammatory Effects of Adalimumab in Treatment of Patients With Major Depressive Disorder: A Pilot, Randomized, Controlled Trial. Clinical Neuropharmacology. 45: 128-134. PMID 36093920 DOI: 10.1097/WNF.0000000000000518  0.32
2022 Zandifar A, Badrfam R, Sanjari Moghaddam H, Akhondzadeh S. Efficacy of Spironolactone as an Adjunctive Therapy to Risperidone to Improve Symptoms of Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled, Clinical Trial. Iranian Journal of Psychiatry. 17: 14-23. PMID 35480128 DOI: 10.18502/ijps.v17i1.8045  0.387
2022 Motamed M, Karimi H, Sanjari Moghaddam H, Taherzadeh Boroujeni S, Sanatian Z, Hasanzadeh A, Khodaei Ardakani MR, Akhondzadeh S. Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. International Clinical Psychopharmacology. 37: 92-101. PMID 35258035 DOI: 10.1097/YIC.0000000000000399  0.371
2022 Talaei A, Dastgheib MS, Soltanifar A, Mokhber N, Akhondzadeh S, Afzaljavan F. Oxcarbazepine versus sodium valproate in treatment of acute mania: a double-blind randomized clinical trial. International Clinical Psychopharmacology. PMID 35121700 DOI: 10.1097/YIC.0000000000000394  0.374
2022 Khadivi A, Shobeiri P, Momtazmaneh S, Samsami FS, Shalbafan M, Shirazi E, Akhondzadeh S. Cilostazol as an adjunctive treatment in major depressive disorder: a pilot randomized, double-blind, and placebo-controlled clinical trial. Psychopharmacology. 239: 551-559. PMID 35072758 DOI: 10.1007/s00213-021-06041-0  0.359
2022 Zarezadeh F, Arbabi M, Shamabadi A, Naderi S, Hasanzadeh A, Ostadpour M, Samsami FS, Akhondzadeh S. Levetiracetam adjunct to quetiapine for the acute manic phase of bipolar disorder: a randomized, double-blind and placebo-controlled clinical trial of efficacy, safety and tolerability. International Clinical Psychopharmacology. 37: 46-53. PMID 34864756 DOI: 10.1097/YIC.0000000000000383  0.392
2021 Badrfam R, Mostafavi SA, Khaleghi A, Akhondzadeh S, Zandifar A, Farid M, Mohammadian Khonsari N, Mohammadi MR. The efficacy of vitamin B6 as an adjunctive therapy to lithium in improving the symptoms of acute mania in patients with bipolar disorder, type 1; a double-blind, randomized, placebo-controlled, clinical trial. Brain and Behavior. 11: e2394. PMID 34662000 DOI: 10.1002/brb3.2394  0.316
2021 Shamabadi A, Akhondzadeh S. Efficacy and tolerability of in treating patients with the diagnosis of depression: a systematic review of randomized controlled trials. Journal of Complementary & Integrative Medicine. PMID 34420270 DOI: 10.1515/jcim-2020-0498  0.335
2021 Zandifar A, Badrfam R, Shamabadi A, Jalilevand S, Pourmirbabaei S, Torkamand F, Sahebolzamani E, Akhondzadeh S. Efficacy of Gemfibrozil as an Adjunct to Sertraline in Major Depressive Disorder, A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial. Iranian Journal of Psychiatry. 16: 52-59. PMID 34054983 DOI: 10.18502/ijps.v16i1.5379  0.408
2021 Masoudi M, Ansari S, Kashani L, Tavolinejad H, Hossein Rashidi B, Esalatmanesh S, Ghazizadeh-Hashemi M, Noorbala AA, Akhondzadeh S. Effect of sertraline on depression severity and prolactin levels in women with polycystic ovary syndrome: a placebo-controlled randomized trial. International Clinical Psychopharmacology. PMID 34030169 DOI: 10.1097/YIC.0000000000000367  0.316
2021 Farajollahi-Moghadam M, Sanjari-Moghaddam H, Ghazizadeh Hasemi M, Sanatian Z, Talaei A, Akhondzadeh S. Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial. International Clinical Psychopharmacology. 36: 140-146. PMID 33724254 DOI: 10.1097/YIC.0000000000000353  0.414
2020 Noroozi A, Motevalian SA, Zarrindast MR, Alaghband-Rad J, Akhondzadeh S. Adding extended-release methylphenidate to psychological intervention for treatment of methamphetamine dependence: A double-blind randomized controlled trial. Medical Journal of the Islamic Republic of Iran. 34: 137. PMID 33437733 DOI: 10.34171/mjiri.34.137  0.341
2020 Hoobehfekr S, Moghaddam HS, Shalbafan M, Hashemi MG, Pirmoradi MM, Sakenian A, Poopak A, Kashefinejad S, Yarahmadi M, Akhondzadeh S. Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry and Clinical Neurosciences. PMID 33247483 DOI: 10.1111/pcn.13180  0.322
2020 Batebi N, Moghaddam HS, Hasanzadeh A, Fakour Y, Mohammadi MR, Akhondzadeh S. Folinic Acid as Adjunctive Therapy in Treatment of Inappropriate Speech in Children with Autism: A Double-Blind and Placebo-Controlled Randomized Trial. Child Psychiatry and Human Development. PMID 33029705 DOI: 10.1007/s10578-020-01072-8  0.319
2020 Ghamari K, Kashani L, Jafarinia M, Tadayon Najafabadi B, Shokraee K, Esalatmanesh S, Akhondzadeh S. Vitamin E and ginseng supplementation to enhance female sexual function: a randomized, double-blind, placebo-controlled, clinical trial. Women & Health. 60: 1164-1173. PMID 32893745 DOI: 10.1080/03630242.2020.1803465  0.367
2020 Moradi K, Ashraf-Ganjouei A, Tavolinejad H, Bagheri S, Akhondzadeh S. The interplay between gut microbiota and autism spectrum disorders: A focus on immunological pathways. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 110091. PMID 32891667 DOI: 10.1016/J.Pnpbp.2020.110091  0.301
2020 Ayatollahi A, Bagheri S, Ashraf-Ganjouei A, Moradi K, Mohammadi MR, Akhondzadeh S. Does Pregnenolone Adjunct to Risperidone Ameliorate Irritable Behavior in Adolescents With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial? Clinical Neuropharmacology. PMID 32815851 DOI: 10.1097/Wnf.0000000000000405  0.383
2020 Firoozeei TS, Barekatain M, Karimi M, Zargaran A, Akhondzadeh S, Rezaeizadeh H. Lavender and dodder combined herbal syrup versus citalopram in major depressive disorder with anxious distress: A double-blind randomized trial. Journal of Integrative Medicine. PMID 32739466 DOI: 10.1016/J.Joim.2020.06.002  0.42
2020 Yousefzadeh F, Sahebolzamani E, Sadri A, Mortezaei A, Aqamolaei A, Mortazavi SH, Shalbafan MR, Ghaffari S, Alikhani R, Mousavi SB, Naderi S, Shamabadi A, Jalilevand S, Akhondzadeh S. 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control. International Clinical Psychopharmacology. 35: 254-262. PMID 32541380 DOI: 10.1097/Yic.0000000000000321  0.505
2020 Rafeiy-Torghabeh M, Ashraf-Ganjouei A, Moradi K, Bagheri S, Mohammadi MR, Akhondzadeh S. Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial. European Child & Adolescent Psychiatry. PMID 32449130 DOI: 10.1007/S00787-020-01562-Z  0.415
2020 Borhannejad F, Shariati B, Naderi S, Shalbafan M, Mortezaei A, Sahebolzamani E, Saeb A, Hosein Mortazavi S, Kamalzadeh L, Aqamolaei A, Ali Noorbala A, Namazi-Shabestari A, Akhondzadeh S. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial. Journal of Clinical Pharmacy and Therapeutics. PMID 32420649 DOI: 10.1111/Jcpt.13177  0.441
2020 Momtazmanesh S, Amirimoghaddam-Yazdi Z, Moghaddam HS, Mohammadi MR, Akhondzadeh S. Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry and Clinical Neurosciences. 74: 398-405. PMID 32347624 DOI: 10.1111/Pcn.13016  0.435
2020 Talaei A, Hosseini FF, Aghili Z, Akhondzadeh S, Asadpour E, Mehramiz NJ, Forouzanfar F. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Canadian Journal of Physiology and Pharmacology. 236-242. PMID 32228235 DOI: 10.1139/Cjpp-2019-0381  0.454
2020 Malek M, Ashraf-Ganjouei A, Moradi K, Bagheri S, Mohammadi MR, Akhondzadeh S. Prednisolone as Adjunctive Treatment to Risperidone in Children With Regressive Type of Autism Spectrum Disorder: A Randomized, Placebo-Controlled Trial. Clinical Neuropharmacology. 43: 39-45. PMID 32168067 DOI: 10.1097/Wnf.0000000000000382  0.409
2020 Moazen-Zadeh E, Bayanati S, Ziafat K, Rezaei F, Mesgarpour B, Akhondzadeh S. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. Journal of Psychopharmacology (Oxford, England). 34: 506-513. PMID 32122230 DOI: 10.1177/0269881120909416  0.431
2020 Araminia B, Shalbafan M, Mortezaei A, Shirazi E, Ghaffari S, Sahebolzamani E, Mortazavi SH, Shariati B, Ardebili ME, Aqamolaei A, Naderi S, Akhondzadeh S. L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders. 267: 131-136. PMID 32063564 DOI: 10.1016/J.Jad.2020.02.020  0.436
2020 Moghaddam HS, Bahmani S, Bayanati S, Mahdavinasa M, Rezaei F, Akhondzadeh S. Efficacy of melatonin as an adjunct in the treatment of acute mania: a double-blind and placebo-controlled trial. International Clinical Psychopharmacology. 35: 81-88. PMID 31743233 DOI: 10.1097/Yic.0000000000000298  0.508
2020 Behmanesh H, Moghaddam HS, Mohammadi MR, Akhondzadeh S. Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Clinical Neuropharmacology. 42: 189-196. PMID 31725473 DOI: 10.1097/Wnf.0000000000000368  0.458
2020 Shakiba M, Moazen-Zadeh E, Noorbala AA, Jafarinia M, Divsalar P, Kashani L, Shahmansouri N, Tafakhori A, Bayat H, Akhondzadeh S. Saffron () versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial. Avicenna Journal of Phytomedicine. 8: 513-523. PMID 30456199  0.371
2020 Arabzadeh S, Zeinoddini A, Mostafavi SA, Hamedi M, Ehyaii A, Ghaleiha A, Zeinoddini A, Akhondzadeh S. Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Iranian Journal of Psychiatry. 13: 1-9. PMID 29892311  0.357
2020 Tajdini M, Aminorroaya A, Tavolinejad H, Tofighi S, Jalali A, Sadeghian S, Akhondzadeh S, Vasheghani-Farahani A, Yadangi S, Shahmansouri N, Bozorgi A. Atomoxetine in patients with recurrent vasovagal syncope for preventing vasovagal attacks and improvement of depression and anxiety: a randomized double-blind placebo-controlled clinical trial European Heart Journal. 41. DOI: 10.1093/ehjci/ehaa946.0713  0.332
2020 Ghaffari S, Ghobadi A, Jamshidi AH, Mortazavi SH, Naderi S, Aqamolaei A, Mortezaei A, Sahebolzamani E, Shamabadi A, Jalilvand S, Daraei B, Shalbafan MR, Akhondzadeh S. Cinnamomum tamala as an adjuvant therapy in the treatment of major depressive disorder: A double-blind, randomized, placebo-controlled clinical trial with placebo control Advances in Integrative Medicine. 7: 141-147. DOI: 10.1016/J.Aimed.2019.12.002  0.545
2019 Kianbakht S, Hajiaghaee R, Akhondzadeh S. Efficacy and safety of Sophora alopecuroides var. alopecuroides seed extract for opioid detoxification: A randomized, double-blind, and placebo-controlled clinical trial. Phytotherapy Research : Ptr. 34: 1108-1113. PMID 31793731 DOI: 10.1002/Ptr.6578  0.369
2019 Hendouei F, Sanjari Moghaddam H, Mohammadi MR, Taslimi N, Rezaei F, Akhondzadeh S. Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double-blind and placebo-controlled randomized trial. Journal of Clinical Pharmacy and Therapeutics. 45: 324-334. PMID 31714621 DOI: 10.1111/Jcpt.13076  0.453
2019 Ahmadpanah M, Ramezanshams F, Ghaleiha A, Akhondzadeh S, Sadeghi Bahmani D, Brand S. Crocus Sativus L. (saffron) versus sertraline on symptoms of depression among older people with major depressive disorders-a double-blind, randomized intervention study. Psychiatry Research. 282: 112613. PMID 31669837 DOI: 10.1016/J.Psychres.2019.112613  0.367
2019 Talaei A, Forouzanfar F, Akhondzadeh S. Medicinal plants in the treatment of obsessive-compulsive disorder: A review. Current Drug Discovery Technologies. PMID 31660838 DOI: 10.2174/1570163816666191011105050  0.335
2019 Akhondzadeh S, Mostafavi SA, Keshavarz SA, Mohammadi MR, Hosseini S, Eshraghian MR. A placebo controlled randomized clinical trial of Crocus sativus L. (saffron) on depression and food craving among overweight women with mild to moderate depression. Journal of Clinical Pharmacy and Therapeutics. PMID 31602695 DOI: 10.1111/Jcpt.13040  0.349
2019 Shalbafan M, Malekpour F, Tadayon Najafabadi B, Ghamari K, Dastgheib SA, Mowla A, Shirazi E, Eftekhar Ardebili M, Ghazizadeh-Hashemi M, Akhondzadeh S. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial. Journal of Psychopharmacology (Oxford, England). 33: 1407-1414. PMID 31575326 DOI: 10.1177/0269881119878177  0.439
2019 Seddighnia A, Tadayon Najafabadi B, Ghamari K, Noorbala AA, Ebrahimi Daryani N, Kashani L, Akhondzadeh S. Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 45: 97-104. PMID 31486103 DOI: 10.1111/Jcpt.13032  0.356
2019 Motaharifard MS, Effatpanah M, Karimi M, Akhondzadeh S, Rahimi H, Yasrebi SA, Nejatbakhsh F. Effect of sweet almond syrup versus methylphenidate in children with ADHD: A randomized triple-blind clinical trial. Complementary Therapies in Clinical Practice. 36: 170-175. PMID 31383435 DOI: 10.1016/J.Ctcp.2019.07.008  0.361
2019 Dehbozorghi S, Bagheri S, Moradi K, Shokraee K, Mohammadi MR, Akhondzadeh S. Efficacy and Safety of Tipepidine as Adjunctive Therapy in Children with Attention-Deficit / Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Psychiatry and Clinical Neurosciences. PMID 31294924 DOI: 10.1111/Pcn.12913  0.404
2019 Mahdavinasab SM, Saghazadeh A, Motamed-Gorji N, Vaseghi S, Mohammadi MR, Alichani R, Akhondzadeh S. Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial. European Child & Adolescent Psychiatry. 28: 1619-1628. PMID 30980177 DOI: 10.1007/S00787-019-01333-5  0.414
2019 Baziar S, Aqamolaei A, Khadem E, Mortazavi SH, Naderi S, Sahebolzamani E, Mortezaei A, Jalilevand S, Mohammadi MR, Shahmirzadi M, Akhondzadeh S. Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study. Journal of Child and Adolescent Psychopharmacology. 29: 205-212. PMID 30741567 DOI: 10.1089/Cap.2018.0146  0.395
2019 Nikoo M, Moazen-Zadeh E, Nikoo N, Javidanbardan S, Kazemi A, Choi F, Vogel M, Gholami A, Tavakoli S, Givaki R, Jazani M, Mohammadian F, Markazi Moghaddam N, Goudarzi N, Schutz C, ... ... Akhondzadeh S, et al. Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial. International Journal of Methods in Psychiatric Research. e1768. PMID 30714249 DOI: 10.1002/Mpr.1768  0.4
2019 Najafabadi BT, Jafarinia M, Ghamari K, Shokraee K, Tadayyon F, Akhondzadeh S. Vitamin E and ginseng combined supplement for treatment of male erectile dysfunction: a double-blind, placebo-controlled, randomized, clinical trial Advances in Integrative Medicine. DOI: 10.1016/J.Aimed.2019.12.001  0.403
2019 Tadyon Najafabadi B, Ghamari K, Kermany Ranjabari T, Noorbala AA, Ebrahimi Daryani N, Vanaki E, Akhondzadeh S. Therapeutic effects of saffron (Crocus sativus) versus fluoxetine on Irritable Bowel Syndrome: A double-blind randomized clinical trial Advances in Integrative Medicine. 6: 167-173. DOI: 10.1016/J.Aimed.2019.01.001  0.435
2018 Farahzadi MH, Moazen-Zadeh E, Razaghi E, Zarrindast MR, Bidaki R, Akhondzadeh S. Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial. Journal of Psychopharmacology (Oxford, England). 33: 305-315. PMID 30526230 DOI: 10.1177/0269881118817166  0.398
2018 Naderi S, Faghih H, Aqamolaei A, Mortazavi SH, Mortezaei A, Sahebolzamani E, Rezaei F, Akhondzadeh S. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control. Psychiatry and Clinical Neurosciences. 73: 169-174. PMID 30488617 DOI: 10.1111/Pcn.12803  0.483
2018 Milajerdi A, Jazayeri S, Shirzadi E, Hashemzadeh N, Azizgol A, Djazayery A, Esmaillzadeh A, Akhondzadeh S. The effects of alcoholic extract of saffron (Crocus satious L.) on mild to moderate comorbid depression-anxiety, sleep quality, and life satisfaction in type 2 diabetes mellitus: A double-blind, randomized and placebo-controlled clinical trial. Complementary Therapies in Medicine. 41: 196-202. PMID 30477839 DOI: 10.1016/J.Ctim.2018.09.023  0.372
2018 Roohi-Azizi M, Torkaman-Boutorabi A, Akhondzadeh S, Nejatisafa AA, Sadat-Shirazi MS, Zarrindast MR. Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice. Physiology & Behavior. 195: 151-157. PMID 30107190 DOI: 10.1016/J.Physbeh.2018.08.002  0.391
2018 Ghajar A, Gholamian F, Tabatabei-Motlagh M, Afarideh M, Rezaei F, Ghazizadeh-Hashemi M, Akhondzadeh S. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Human Psychopharmacology. 33: e2662. PMID 29901250 DOI: 10.1002/Hup.2662  0.434
2018 Khalaj M, Saghazadeh A, Shirazi E, Shalbafan MR, Alavi K, Shooshtari MH, Laksari FY, Hosseini M, Mohammadi MR, Akhondzadeh S. Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. Journal of Psychiatric Research. 103: 104-111. PMID 29807317 DOI: 10.1016/J.Jpsychires.2018.04.022  0.48
2018 Keshavarz SA, Mostafavi SA, Akhondzadeh S, Mohammadi MR, Hosseini S, Eshraghian MR, Chamari M. Omega-3 supplementation effects on body weight and depression among dieter women with co-morbidity of depression and obesity compared with the placebo: A randomized clinical trial. Clinical Nutrition Espen. 25: 37-43. PMID 29779816 DOI: 10.1016/J.Clnesp.2018.03.001  0.341
2018 Arabzadeh S, Hakkikazazi E, Shahmansouri N, Tafakhori A, Ghajar A, Jafarinia M, Akhondzadeh S. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. Journal of Affective Disorders. 235: 236-241. PMID 29660637 DOI: 10.1016/J.Jad.2018.02.056  0.425
2018 Ghazizadeh-Hashemi M, Ghajar A, Shalbafan MR, Ghazizadeh-Hashemi F, Afarideh M, Malekpour F, Ghaleiha A, Ardebili ME, Akhondzadeh S. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. Journal of Affective Disorders. 232: 127-133. PMID 29486338 DOI: 10.1016/J.Jad.2018.02.057  0.448
2018 Ghajar A, Aghajan-Nashtaei F, Afarideh M, Mohammadi MR, Akhondzadeh S. l-Carnosine as Adjunctive Therapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Journal of Child and Adolescent Psychopharmacology. 28: 331-338. PMID 29469593 DOI: 10.1089/Cap.2017.0157  0.379
2018 Ghajar A, Khoaie-Ardakani MR, Shahmoradi Z, Alavi AR, Afarideh M, Shalbafan MR, Ghazizadeh-Hashemi M, Akhondzadeh S. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Psychiatry Research. 262: 94-101. PMID 29427913 DOI: 10.1016/J.Psychres.2018.02.012  0.483
2018 Kashani L, Esalatmanesh S, Eftekhari F, Salimi S, Foroughifar T, Etesam F, Safiaghdam H, Moazen-Zadeh E, Akhondzadeh S. Efficacy of Crocus sativus (saffron) in treatment of major depressive disorder associated with post-menopausal hot flashes: a double-blind, randomized, placebo-controlled trial. Archives of Gynecology and Obstetrics. PMID 29332222 DOI: 10.1007/S00404-018-4655-2  0.461
2018 Shakiba M, Moazenzadeh E, Noorbala AA, Jafarinia M, Divsalar P, Kashani L, Shahmansouri N, Tafakhori A, Bayat H, Akhondzadeh S. Saffron ( Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial Avicenna Journal of Phytomedicine. 8: 513-523. DOI: 10.22038/Ajp.2018.28835.2020  0.48
2018 Divsalar P, Noorbala AA, Moazen-Zadeh E, Jafarinia M, Shakiba M, Shahmansouri N, Ghazizadeh-Hashemi M, Etesam F, Akhondzadeh S. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: Placebo-controlled trial Advances in Integrative Medicine. 5: 69-74. DOI: 10.1016/J.Aimed.2018.01.001  0.479
2017 Moazen-Zadeh E, Abbasi SH, Safi-Aghdam H, Shahmansouri N, Arjmandi-Beglar A, Hajhosseinn Talasaz A, Salehiomran A, Forghani S, Akhondzadeh S. Effects of Saffron on Cognition, Anxiety, and Depression in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Double-Blind Placebo-Controlled Trial. Journal of Alternative and Complementary Medicine (New York, N.Y.). PMID 29185780 DOI: 10.1089/Acm.2017.0173  0.33
2017 Morabbi MJ, Razaghi E, Moazen-Zadeh E, Safiaghdam H, Zarrindast MR, Vousoghi N, Akhondzadeh S. Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. International Clinical Psychopharmacology. PMID 29064909 DOI: 10.1097/Yic.0000000000000200  0.508
2017 Esalatmanesh S, Biuseh M, Noorbala AA, Mostafavi SA, Rezaei F, Mesgarpour B, Mohammadinejad P, Akhondzadeh S. Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind Randomized Clinical Trial. Iranian Journal of Psychiatry. 12: 154-162. PMID 29062366  0.376
2017 Hajizadeh-Zaker R, Ghajar A, Mesgarpour B, Afarideh M, Mohammadi MR, Akhondzadeh S. l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology. PMID 29027815 DOI: 10.1089/Cap.2017.0026  0.378
2017 Moazen-Zadeh E, Shirzad F, Karkhaneh-Yousefi MA, Khezri R, Mohammadi MR, Akhondzadeh S. Simvastatin as an Adjunctive Therapy to Risperidone in Treatment of Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Journal of Child and Adolescent Psychopharmacology. PMID 28719227 DOI: 10.1089/Cap.2017.0055  0.448
2017 Kashani L, Shams N, Moazen-Zadeh E, Karkhaneh-Yousefi MA, Sadighi G, Khodaie-Ardakani MR, Rezaei F, Rahiminejad F, Akhondzadeh S. Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial. Journal of Psychiatric Research. 94: 70-77. PMID 28688338 DOI: 10.1016/J.Jpsychires.2017.06.011  0.475
2017 Alamdarsaravi M, Ghajar A, Noorbala AA, Arbabi M, Emami A, Shahei F, Mirzania M, Jafarinia M, Afarideh M, Akhondzadeh S. Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: A randomized double-blind, placebo controlled trial. Psychiatry Research. 255: 59-65. PMID 28528242 DOI: 10.1016/J.Psychres.2017.05.029  0.486
2017 Arabzadeh S, Shahhossenie M, Mesgarpour B, Rezaei F, Shalbafan MR, Ghiasi Z, Akhondzadeh S. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. Human Psychopharmacology. PMID 28485008 DOI: 10.1002/Hup.2584  0.357
2017 Rezaei F, Mesgarpour B, Jeddian A, Zeionoddini A, Mohammadinejad P, Salardini E, Shahriari M, Zeinoddini A, Akhondzadeh S. Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study. Human Psychopharmacology. PMID 28421639 DOI: 10.1002/Hup.2583  0.397
2017 Mousavi SY, Khezri R, Karkhaneh-Yousefi MA, Mohammadinejad P, Gholamian F, Mohammadi MR, Zeinoddini A, Akhondzadeh S. A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents with Acute Bipolar Mania. Journal of Child and Adolescent Psychopharmacology. PMID 28409660 DOI: 10.1089/Cap.2016.0207  0.382
2017 Mostafavi SA, Solhi M, Mohammadi MR, Akhondzadeh S. Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology. PMID 28339282 DOI: 10.1089/Cap.2016.0046  0.407
2017 Roohi-Azizi M, Arabzadeh S, Amidfar M, Salimi S, Zarindast MR, Talaei A, Akhondzadeh S. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Neuropharmacology. 40: 1-5. PMID 28085707 DOI: 10.1097/Wnf.0000000000000185  0.438
2017 Milajerdi A, Jazayeri S, Bitarafan V, Hashemzadeh N, Shirzadi E, Derakhshan Z, Mahmoodi M, Rayati A, Djazayeri A, Akhondzadeh S. The effect of saffron ( Crocus sativus L.) hydro-alcoholic extract on liver and renal functions in type 2 diabetic patients: A double-blinded randomized and placebo control trial Journal of Nutrition & Intermediary Metabolism. 9: 6-11. DOI: 10.1016/J.Jnim.2017.07.002  0.314
2016 Akhondzadeh S, Moazen-Zadeh E. More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia. Evidence-Based Mental Health. PMID 28011708 DOI: 10.1136/Eb-2016-102500  0.472
2016 Tajik-Esmaeeli S, Moazen-Zadeh E, Abbasi N, Shariat SV, Rezaei F, Salehi B, Akhondzadeh S. Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial. International Clinical Psychopharmacology. PMID 27941358 DOI: 10.1097/Yic.0000000000000159  0.449
2016 Amidfar M, Khiabany M, Kohi A, Salardini E, Arbabi M, Roohi Azizi M, Zarrindast MR, Mohammadinejad P, Zeinoddini A, Akhondzadeh S. Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. Journal of Clinical Pharmacy and Therapeutics. PMID 27809351 DOI: 10.1111/Jcpt.12469  0.453
2016 Ghajar A, Neishabouri SM, Velayati N, Jahangard L, Matinnia N, Haghighi M, Ghaleiha A, Afarideh M, Salimi S, Meysamie A, Akhondzadeh S. Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial. Pharmacopsychiatry. 50: 152-160. PMID 27701683 DOI: 10.1055/S-0042-116159  0.487
2016 Kashani L, Eslatmanesh S, Saedi N, Niroomand N, Ebrahimi M, Hosseinian M, Foroughifar T, Salimi S, Akhondzadeh S. Comparison of Saffron versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial. Pharmacopsychiatry. 50: 64-68. PMID 27595298 DOI: 10.1055/S-0042-115306  0.484
2016 Esalatmanesh S, Abrishami Z, Zeinoddini A, Rahiminejad F, Sadeghi M, Najarzadegan MR, Shalbafan MR, Akhondzadeh S. Minocycline combination therapy with fluvoxamine in moderate to severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial. Psychiatry and Clinical Neurosciences. PMID 27488081 DOI: 10.1111/Pcn.12430  0.447
2016 Jafarinia M, Afarideh M, Tafakhori A, Arbabi M, Ghajar A, Noorbala AA, Saravi MA, Agah E, Akhondzadeh S. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. Journal of Affective Disorders. 204: 1-8. PMID 27317968 DOI: 10.1016/J.Jad.2016.05.076  0.393
2016 Salardini E, Zeinoddini A, Kohi A, Mohammadi MR, Mohammadinejad P, Khiabany M, Shahriari M, Akhondzadeh S. Agomelatine as a Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Double-Blind, Randomized Clinical Trial. Journal of Child and Adolescent Psychopharmacology. PMID 27286139 DOI: 10.1089/Cap.2016.0024  0.387
2016 Khajehnasiri F, Akhondzadeh S, Mortazavi SB, Allameh A, Sotoudeh G, Khavanin A, Zamanian Z. Are Supplementation of Omega-3 and Ascorbic Acid Effective in Reducing Oxidative Stress and Depression among Depressed Shift Workers? International Journal For Vitamin and Nutrition Research. Internationale Zeitschrift Fur Vitamin- Und Ernahrungsforschung. Journal International De Vitaminologie Et De Nutrition. 1-12. PMID 27164176 DOI: 10.1024/0300-9831/A000249  0.304
2016 Ghaleiha A, Alikhani R, Kazemi MR, Mohammadi MR, Mohammadinejad P, Zeinoddini A, Hamedi M, Shahriari M, Keshavarzi Z, Akhondzadeh S. Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology. PMID 27128958 DOI: 10.1089/Cap.2015.0175  0.403
2016 Emamzadehfard S, Kamaloo A, Paydary K, Ahmadipour A, Zeinoddini A, Ghaleiha A, Mohammadinejad P, Zeinoddini A, Akhondzadeh S. Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive Compulsive Disorder: Randomized, Double-blind, Placebo-Controlled Study. Psychiatry and Clinical Neurosciences. PMID 27106362 DOI: 10.1111/Pcn.12394  0.478
2016 Paydary K, Akamaloo A, Ahmadipour A, Pishgar F, Emamzadehfard S, Akhondzadeh S. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 41: 214-9. PMID 26931055 DOI: 10.1111/Jcpt.12370  0.443
2016 Nikbakhat M-, Arabzadeh S, Zeinoddini A, Khalili Z, Rezaei F, Mohammadinejad P, Ghaleiha A, Akhondzadeh S. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study. Pharmacopsychiatry. 49: 162-169. PMID 26902281 DOI: 10.1055/S-0042-101557  0.467
2016 Iranpour N, Zandifar A, Farokhnia M, Goguol A, Yekehtaz H, Khodaie-Ardakani MR, Salehi B, Esalatmanesh S, Zeionoddini A, Mohammadinejad P, Zeinoddini A, Akhondzadeh S. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. Human Psychopharmacology. PMID 26856695 DOI: 10.1002/Hup.2517  0.384
2016 Salardini E, Zeinoddini A, Mohammadinejad P, Khodaie-Ardakani MR, Zahraei N, Zeinoddini A, Akhondzadeh S. Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Research. 75: 24-30. PMID 26800392 DOI: 10.1016/J.Jpsychires.2016.01.003  0.534
2015 Emadi-Kouchak H, Mohammadinejad P, Asadollahi-Amin A, Rasoulinejad M, Zeinoddini A, Yalda A, Akhondzadeh S. Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: a double-blind, placebo-controlled, randomized trial. International Clinical Psychopharmacology. PMID 26465919 DOI: 10.1097/Yic.0000000000000098  0.435
2015 Kargar M, Yoosefi A, Akhondzadeh S, Artonian V, Ashouri A, Ghaeli P. Effect of Adjunctive Celecoxib on BDNF in Manic Patients Undergoing Electroconvulsive Therapy: a Randomized Double Blind Controlled Trial. Pharmacopsychiatry. PMID 26398281 DOI: 10.1055/S-0035-1559667  0.378
2015 Arabzadeh S, Ameli N, Zeinoddini A, Rezaei F, Farokhnia M, Mohammadinejad P, Ghaleiha A, Akhondzadeh S. Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. Bipolar Disorders. 17: 606-14. PMID 26291962 DOI: 10.1111/Bdi.12324  0.389
2015 Ghaleiha A, Rasa SM, Nikoo M, Farokhnia M, Mohammadi MR, Akhondzadeh S. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism. Psychiatry Research. PMID 26208985 DOI: 10.1016/J.Psychres.2015.07.043  0.457
2015 Mohammadinejad P, Arya P, Esfandbod M, Kaviani A, Najafi M, Kashani L, Zeinoddini A, Emami SA, Akhondzadeh S. Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial. The Annals of Pharmacotherapy. PMID 26139640 DOI: 10.1177/1060028015592215  0.319
2015 Khodaie-Ardakani MR, Khosravi M, Zarinfard R, Nejati S, Mohsenian A, Tabrizi M, Akhondzadeh S. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia. Acta Medica Iranica. 53: 337-45. PMID 26069170  0.386
2015 Jafari S, Ashrafizadeh SG, Zeinoddini A, Rasoulinejad M, Entezari P, Seddighi S, Akhondzadeh S. Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial. Journal of Clinical Pharmacy and Therapeutics. 40: 441-6. PMID 26009929 DOI: 10.1111/Jcpt.12287  0.389
2015 Abbasi SH, Mohammadinejad P, Shahmansouri N, Salehiomran A, Beglar AA, Zeinoddini A, Forghani S, Akhondzadeh S. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders. 183: 149-55. PMID 26005776 DOI: 10.1016/J.Jad.2015.04.049  0.347
2015 Shalbafan M, Mohammadinejad P, Shariat SV, Alavi K, Zeinoddini A, Salehi M, Askari N, Akhondzadeh S. Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial. Pharmacopsychiatry. 48: 136-40. PMID 25959196 DOI: 10.1055/S-0035-1549929  0.417
2015 Gougol A, Zareh-Mohammadi N, Raheb S, Farokhnia M, Salimi S, Iranpour N, Yekehtaz H, Akhondzadeh S. Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial. Journal of Psychopharmacology (Oxford, England). 29: 575-81. PMID 25827645 DOI: 10.1177/0269881115578160  0.491
2015 Zeinoddini A, Sorayani M, Hassanzadeh E, Arbabi M, Farokhnia M, Salimi S, Ghaleiha A, Akhondzadeh S. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depression and Anxiety. 32: 167-73. PMID 25620378 DOI: 10.1002/Da.22340  0.425
2015 Rezaei F, Emami M, Zahed S, Morabbi MJ, Farahzadi M, Akhondzadeh S. Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial. Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 23: 2. PMID 25588930 DOI: 10.1186/S40199-015-0092-Y  0.476
2015 Nikoo M, Radnia H, Farokhnia M, Mohammadi MR, Akhondzadeh S. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clinical Neuropharmacology. 38: 11-7. PMID 25580916 DOI: 10.1097/Wnf.0000000000000063  0.425
2015 Vafaeinasab MR, Farahzadi MH, Razaghi OM, Fallahzadeh RA, Lotfi MH, Akhondzadeh S. Investigation of Affecting Factors on Persistence in the Treatment of Patients under Methadone Maintenance Therapy in Addiction Therapy Centers, Yazd-Iran Health. 7: 606-616. DOI: 10.4236/Health.2015.75072  0.327
2014 Mostafavi A, Solhi M, Mohammadi MR, Hamedi M, Keshavarzi M, Akhondzadeh S. Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial. Acta Medica Iranica. 52: 734-9. PMID 25369006  0.315
2014 Zeinoddini A, Ahadi M, Farokhnia M, Rezaei F, Tabrizi M, Akhondzadeh S. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial. Journal of Psychiatric Research. 59: 125-31. PMID 25227564 DOI: 10.1016/J.Jpsychires.2014.08.016  0.451
2014 Farokhnia M, Shafiee Sabet M, Iranpour N, Gougol A, Yekehtaz H, Alimardani R, Farsad F, Kamalipour M, Akhondzadeh S. Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. Human Psychopharmacology. 29: 351-9. PMID 25163440 DOI: 10.1002/Hup.2412  0.328
2014 Ghanizadeh A, Rezaee Z, Dehbozorgi S, Berk M, Akhondzadeh S. Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial. Psychiatry Research. 219: 431-5. PMID 25017614 DOI: 10.1016/J.Psychres.2014.06.039  0.467
2014 Kianimehr G, Fatehi F, Hashempoor S, Khodaei-Ardakani MR, Rezaei F, Nazari A, Kashani L, Akhondzadeh S. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 22: 55. PMID 25012765 DOI: 10.1186/2008-2231-22-55  0.456
2014 Sahraian A, Bigdeli M, Ghanizadeh A, Akhondzadeh S. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial. Journal of Affective Disorders. 166: 201-5. PMID 25012432 DOI: 10.1016/J.Jad.2014.05.015  0.486
2014 Heidari M, Zarei M, Hosseini SM, Taghvaei R, Maleki H, Tabrizi M, Fallah J, Akhondzadeh S. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. International Clinical Psychopharmacology. 29: 344-50. PMID 24850229 DOI: 10.1097/Yic.0000000000000043  0.484
2014 Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A, Akhondzadeh S. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 846-55. PMID 24636461 DOI: 10.1016/J.Euroneuro.2014.02.001  0.478
2014 Kargar M, Yousefi A, Mojtahedzadeh M, Akhondzadeh S, Artounian V, Abdollahi A, Ahmadvand A, Ghaeli P. Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study. Swiss Medical Weekly. 144: w13880. PMID 24554598 DOI: 10.4414/Smw.2014.13880  0.407
2014 Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, Rezaei F, Salehi B, Yekehtaz H, Ashrafi M, Tabrizi M, Akhondzadeh S. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Research. 215: 540-6. PMID 24480077 DOI: 10.1016/J.Psychres.2013.12.051  0.456
2014 Shahmansouri N, Farokhnia M, Abbasi SH, Kassaian SE, Noorbala Tafti AA, Gougol A, Yekehtaz H, Forghani S, Mahmoodian M, Saroukhani S, Arjmandi-Beglar A, Akhondzadeh S. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. Journal of Affective Disorders. 155: 216-22. PMID 24289892 DOI: 10.1016/J.Jad.2013.11.003  0.449
2014 Yoosefi A, Sepehri AS, Kargar M, Akhondzadeh S, Sadeghi M, Rafei A, Alimadadi A, Ghaeli P. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study. The Journal of Ect. 30: 15-21. PMID 24091902 DOI: 10.1097/Yct.0B013E3182A4B4C6  0.438
2014 Farokhnia M, Sabzabadi M, Pourmahmoud H, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Akhondzadeh S. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacology. 231: 533-42. PMID 24013610 DOI: 10.1007/S00213-013-3261-Z  0.409
2013 Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clinical Neuropharmacology. 36: 185-92. PMID 24201233 DOI: 10.1097/Wnf.0000000000000001  0.437
2013 Mohammadi MR, Yadegari N, Hassanzadeh E, Farokhnia M, Yekehtaz H, Mirshafiee O, Akhondzadeh S. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology. 36: 179-84. PMID 24201232 DOI: 10.1097/Wnf.0B013E3182A9339D  0.478
2013 Ghaleiha A, Ghyasvand M, Mohammadi MR, Farokhnia M, Yadegari N, Tabrizi M, Hajiaghaee R, Yekehtaz H, Akhondzadeh S. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology (Oxford, England). 28: 677-685. PMID 24132248 DOI: 10.1177/0269881113508830  0.477
2013 Saroukhani S, Emami-Parsa M, Modabbernia A, Ashrafi M, Farokhnia M, Hajiaghaee R, Akhondzadeh S. Aspirin for treatment of lithium-associated sexual dysfunction in men: randomized double-blind placebo-controlled study. Bipolar Disorders. 15: 650-6. PMID 23924261 DOI: 10.1111/Bdi.12108  0.461
2013 Khajehnasiri F, Mortazavi SB, Allameh A, Akhondzadeh S. Effect of omega-3 and ascorbic acid on inflammation markers in depressed shift workers in Shahid Tondgoyan Oil Refinery, Iran: a randomized double-blind placebo-controlled study. Journal of Clinical Biochemistry and Nutrition. 53: 36-40. PMID 23874068 DOI: 10.3164/Jcbn.12-98  0.364
2013 Ghaleiha A, Mohammadi E, Mohammadi MR, Farokhnia M, Modabbernia A, Yekehtaz H, Ashrafi M, Hassanzadeh E, Akhondzadeh S. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Paediatric Drugs. 15: 505-14. PMID 23821414 DOI: 10.1007/S40272-013-0036-2  0.477
2013 Khajehnasiri F, Mortazavi SB, Allameh A, Akhondzadeh S, Hashemi H. Total antioxidant capacity and malondialdehyde in depressive rotational shift workers. Journal of Environmental and Public Health. 2013: 150693. PMID 23690799 DOI: 10.1155/2013/150693  0.312
2013 Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H, Hajiaghaee R, Tabrizi M, Akhondzadeh S. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology. 33: 336-42. PMID 23609382 DOI: 10.1097/Jcp.0B013E31828B50A7  0.501
2013 Akhondzadeh S, Gerbarg PL, Brown RP. Nutrients for prevention and treatment of mental health disorders. The Psychiatric Clinics of North America. 36: 25-36. PMID 23538074 DOI: 10.1016/J.Psc.2012.12.003  0.424
2013 Noroozian M, Ghasemi S, Hosseini SM, Modabbernia A, Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Rezaei F, Salehi B, Ashrafi M, Yekehtaz H, Tabrizi M, Akhondzadeh S. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology. 228: 595-602. PMID 23515583 DOI: 10.1007/S00213-013-3064-2  0.448
2013 Dabaghzadeh F, Ghaeli P, Khalili H, Alimadadi A, Jafari S, Akhondzadeh S, Khazaeipour Z. Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial. Aids Patient Care and Stds. 27: 146-54. PMID 23442031 DOI: 10.1089/Apc.2012.0410  0.417
2013 Khodaie-Ardakani MR, Seddighi S, Modabbernia A, Rezaei F, Salehi B, Ashrafi M, Shams-Alizadeh N, Mohammad-Karimi M, Esfandiari GR, Hajiaghaee R, Akhondzadeh S. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research. 47: 472-8. PMID 23375406 DOI: 10.1016/J.Jpsychires.2013.01.011  0.484
2013 Kashani L, Raisi F, Saroukhani S, Sohrabi H, Modabbernia A, Nasehi AA, Jamshidi A, Ashrafi M, Mansouri P, Ghaeli P, Akhondzadeh S. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Human Psychopharmacology. 28: 54-60. PMID 23280545 DOI: 10.1002/Hup.2282  0.377
2013 Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study. Cns Drugs. 27: 57-65. PMID 23233269 DOI: 10.1007/S40263-012-0022-1  0.458
2013 Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. Journal of Psychiatric Research. 47: 175-80. PMID 23063327 DOI: 10.1016/J.Jpsychires.2012.09.015  0.486
2013 Ghaleiha A, Asadabadi M, Mohammadi MR, Shahei M, Tabrizi M, Hajiaghaee R, Hassanzadeh E, Akhondzadeh S. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 16: 783-9. PMID 22999292 DOI: 10.1017/S1461145712000880  0.465
2013 Kashani L, Omidvar T, Farazmand B, Modabbernia A, Ramzanzadeh F, Tehraninejad ES, Ashrafi M, Tabrizi M, Akhondzadeh S. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology. 38: 767-76. PMID 22999261 DOI: 10.1016/J.Psyneuen.2012.08.010  0.407
2013 Asadabadi M, Mohammadi MR, Ghanizadeh A, Modabbernia A, Ashrafi M, Hassanzadeh E, Forghani S, Akhondzadeh S. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology. 225: 51-9. PMID 22782459 DOI: 10.1007/S00213-012-2796-8  0.429
2012 Faghihi T, Jahed A, Mahmoudi-Gharaei J, Sharifi V, Akhondzadeh S, Ghaeli P. Role of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial. Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 20: 43. PMID 23351198 DOI: 10.1186/2008-2231-20-43  0.387
2012 Mohammadi MR, Hafezi P, Galeiha A, Hajiaghaee R, Akhondzadeh S. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study. Acta Medica Iranica. 50: 723-8. PMID 23292622  0.342
2012 Khajavi D, Farokhnia M, Modabbernia A, Ashrafi M, Abbasi SH, Tabrizi M, Akhondzadeh S. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 73: 1428-33. PMID 23146150 DOI: 10.4088/Jcp.12M07706  0.51
2012 Askari N, Moin M, Sanati M, Tajdini M, Hosseini SM, Modabbernia A, Najand B, Salimi S, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. Cns Drugs. 26: 883-92. PMID 22873680 DOI: 10.2165/11635850-000000000-00000  0.454
2012 Jafarinia M, Mohammadi MR, Modabbernia A, Ashrafi M, Khajavi D, Tabrizi M, Yadegari N, Akhondzadeh S. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. Human Psychopharmacology. 27: 411-8. PMID 22806822 DOI: 10.1002/Hup.2242  0.408
2012 Modabbernia A, Sohrabi H, Nasehi AA, Raisi F, Saroukhani S, Jamshidi A, Tabrizi M, Ashrafi M, Akhondzadeh S. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology. 223: 381-8. PMID 22552758 DOI: 10.1007/S00213-012-2729-6  0.471
2012 Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia MJ, Akhondzadeh S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 2093-100. PMID 22549115 DOI: 10.1038/Npp.2012.58  0.482
2012 Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. Journal of Affective Disorders. 141: 308-14. PMID 22516310 DOI: 10.1016/J.Jad.2012.03.033  0.39
2012 Hasanzadeh E, Mohammadi MR, Ghanizadeh A, Rezazadeh SA, Tabrizi M, Rezaei F, Akhondzadeh S. A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders. Child Psychiatry and Human Development. 43: 674-82. PMID 22392415 DOI: 10.1007/S10578-012-0292-3  0.456
2012 Arbabi M, Bagheri M, Rezaei F, Ahmadi-Abhari SA, Tabrizi M, Khalighi-Sigaroudi F, Akhondzadeh S. A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. Psychopharmacology. 220: 591-8. PMID 21947320 DOI: 10.1007/S00213-011-2513-Z  0.472
2012 Khajehnasiri F, Mortazavi SB, Allameh AA, Akhondzadeh S. Serum Level of Cortisol, hsCRP and IL-6 in Depressed Rotational Shift Workers Thrita Journal of Medical Sciences. 1: 139-44. DOI: 10.5812/Thrita.8644  0.312
2011 Abolfazli R, Hosseini M, Ghanizadeh A, Ghaleiha A, Tabrizi M, Raznahan M, Golalizadeh M, Akhondzadeh S. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depression and Anxiety. 28: 297-302. PMID 21456039 DOI: 10.1002/Da.20801  0.517
2011 Ghaleiha A, Honarbakhsh N, Boroumand MA, Jafarinia M, Tabrizi M, Rezaei F, Raznahan M, Akhondzadeh S. Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. Human Psychopharmacology. 26: 120-4. PMID 21412846 DOI: 10.1002/Hup.1176  0.403
2011 Abbasi SH, Heidari S, Mohammadi MR, Tabrizi M, Ghaleiha A, Akhondzadeh S. Acetyl-L-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a placebo-controlled trial. Child Psychiatry and Human Development. 42: 367-75. PMID 21336630 DOI: 10.1007/S10578-011-0220-Y  0.432
2011 Akhondzadeh S, Ghayyoumi R, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, Naderi M, Ghebleh F, Tabrizi M, Rezazadeh SA. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology. 213: 809-15. PMID 20949350 DOI: 10.1007/S00213-010-2044-Z  0.476
2011 Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, Naderi M, Ghebleh F, Ahmadi-Abhari SA, Sadeghi M, Tabrizi M, Akhondzadeh S. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. Journal of Affective Disorders. 129: 327-31. PMID 20843556 DOI: 10.1016/J.Jad.2010.08.015  0.475
2011 Jafari P, Ghanizadeh A, Akhondzadeh S, Mohammadi MR. Health-related quality of life of Iranian children with attention deficit/hyperactivity disorder. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 20: 31-6. PMID 20686924 DOI: 10.1007/S11136-010-9722-5  0.307
2011 Mohammadi MR, Salmanian M, Akhondzadeh S. Autism spectrum disorders in Iran Iranian Journal of Child Neurology. 5: 1-9. DOI: 10.5772/38965  0.326
2011 Davari-Ashtiani R, Parvaresh N, Akhondzadeh S. Gabapentin as a combination treatment with lithium in adolescents with bipolar disorder International Clinical Psychopharmacology. 26: e40. DOI: 10.1097/01.Yic.0000405697.15125.C1  0.316
2011 Modabbernia A, Ashrafi M, Rahiminejad F, Akhondzadeh S. Fc22-04 Effect of folic acid add-on treatment in patients with acute mania on clinical symptoms and urinary 6-sulfatoxymelatonin: double blind placebo-controlled trial European Psychiatry. 26: 1937-1937. DOI: 10.1016/S0924-9338(11)73641-0  0.423
2010 Mohammadi MR, Kazemi MR, Zia E, Rezazadeh SA, Tabrizi M, Akhondzadeh S. Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. Human Psychopharmacology. 25: 560-5. PMID 21312290 DOI: 10.1002/Hup.1154  0.451
2010 Ghaleiha A, Noorbala AA, Farnaghi F, Hajiazim M, Akhondzadeh S. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. Journal of Clinical Psychopharmacology. 30: 678-82. PMID 21105281 DOI: 10.1097/Jcp.0B013E3181Fa8720  0.486
2010 Zarinara AR, Mohammadi MR, Hazrati N, Tabrizi M, Rezazadeh SA, Rezaie F, Akhondzadeh S. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Human Psychopharmacology. 25: 530-5. PMID 20860068 DOI: 10.1002/Hup.1148  0.451
2010 Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SSh, Yousefi MH, Alimardani R, Jamshidi A, Zare F, Moradi A. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 35: 581-8. PMID 20831681 DOI: 10.1111/J.1365-2710.2009.01133.X  0.411
2010 Rezaei V, Mohammadi MR, Ghanizadeh A, Sahraian A, Tabrizi M, Rezazadeh SA, Akhondzadeh S. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 1269-72. PMID 20637249 DOI: 10.1016/J.Pnpbp.2010.07.005  0.45
2010 Abbasi SH, Behpournia H, Ghoreshi A, Salehi B, Raznahan M, Rezazadeh SA, Rezaei F, Akhondzadeh S. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophrenia Research. 116: 101-6. PMID 19959338 DOI: 10.1016/J.Schres.2009.11.008  0.459
2010 Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SS, Yousefi MH, Alimardani R, Jamshidi A, Rezazadeh SA, Yousefi A, Zare F, Moradi A, Vossoughi A. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. Psychopharmacology. 207: 637-43. PMID 19838862 DOI: 10.1007/S00213-009-1706-1  0.415
2010 Salehi B, Imani R, Mohammadi MR, Fallah J, Mohammadi M, Ghanizadeh A, Tasviechi AA, Vossoughi A, Rezazadeh SA, Akhondzadeh S. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 76-80. PMID 19815048 DOI: 10.1016/J.Pnpbp.2009.09.026  0.421
2010 Akhondzadeh S, Fallah J, Mohammadi MR, Imani R, Mohammadi M, Salehi B, Ghanizadeh A, Raznahan M, Mohebbi-Rasa S, Rezazadeh SA, Forghani S. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 32-6. PMID 19772883 DOI: 10.1016/J.Pnpbp.2009.09.012  0.45
2009 Salmasi FB, Jazayeri M, Ghaeli P, Hashemian F, Akhondzadeh S, Raisi F, Hosseini SH, Setareh MJ, Khavidaki SD. Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine. Journal of Clinical Psychopharmacology. 29: 182-3. PMID 19512983 DOI: 10.1097/Jcp.0B013E31819A6Aa2  0.313
2009 Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depression and Anxiety. 26: 607-11. PMID 19496103 DOI: 10.1002/Da.20589  0.485
2009 Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Research. 168: 234-7. PMID 19439364 DOI: 10.1016/J.Psychres.2008.06.024  0.429
2009 Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, Forghani S. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophrenia Research. 107: 206-12. PMID 18789844 DOI: 10.1016/J.Schres.2008.08.004  0.42
2008 Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32: 1879-83. PMID 18801405 DOI: 10.1016/J.Pnpbp.2008.08.020  0.453
2008 Akhondzadeh S, Gerami M, Noroozian M, Karamghadiri N, Ghoreishi A, Abbasi SH, Rezazadeh SA. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32: 1810-5. PMID 18727948 DOI: 10.1016/J.Pnpbp.2008.08.001  0.449
2008 Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, Akhondzadeh S. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. Bjog : An International Journal of Obstetrics and Gynaecology. 115: 515-9. PMID 18271889 DOI: 10.1111/J.1471-0528.2007.01652.X  0.474
2008 Salimi S, Fotouhi A, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Mohammadi MR, Noorbala AA, Ahmadi-Abhari SA, Hajiazim M, Abbasi SH, Akhondzadeh S. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32: 726-32. PMID 18096287 DOI: 10.1016/J.Pnpbp.2007.11.021  0.462
2008 Amiri A, Noorbala AA, Nejatisafa AA, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Hajiazim M, Raznahan M, Akhondzadeh S. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Human Psychopharmacology. 23: 79-86. PMID 17972359 DOI: 10.1002/Hup.902  0.457
2008 Akhondzadeh S, Tajdar H, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Shabstari OL, Ghelichnia HA. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry and Human Development. 39: 237-45. PMID 17929164 DOI: 10.1007/S10578-007-0084-3  0.47
2008 Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S. Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32: 145-9. PMID 17765380 DOI: 10.1016/J.Pnpbp.2007.07.025  0.42
2008 Ahmadi-Abhari SA, Akhondzadeh S, Assadi SM, Shabestari OL, Farzanehgan ZM, Kamlipour A. Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial: Baclofen versus clonidine Journal of Clinical Pharmacy and Therapeutics. 26: 67-71. DOI: 10.1111/J.1365-2710.2001.00325.X  0.42
2008 Akhondzadeh S, Ahmadi-Abhari SA, Assadi SM, Shabestari OL, Kashani AR, Farzanehgan ZM. Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal: Baclofen versus clonidine for opiate withdrawal Journal of Clinical Pharmacy and Therapeutics. 25: 347-353. DOI: 10.1111/J.1365-2710.2000.00295.X  0.406
2007 Togha M, Akhondzadeh S, Motamedi M, Ahmadi B, Razeghi S. Allopurinol as adjunctive therapy in intractable epilepsy: a double-blind and placebo-controlled trial. Archives of Medical Research. 38: 313-6. PMID 17350481 DOI: 10.1016/J.Arcmed.2006.10.010  0.385
2007 Mohammadi MR, Akhondzadeh S. Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Expert Review of Neurotherapeutics. 7: 195-201. PMID 17286552 DOI: 10.1586/14737175.7.2.195  0.348
2007 Rokni-Yazdi H, Sotoudeh H, Akhondzadeh S, Sotoudeh E, Asadi H, Shakiba M. Antidepressant-like effect of magnetic resonance imaging-based stimulation in mice. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 31: 503-9. PMID 17218047 DOI: 10.1016/J.Pnpbp.2006.11.021  0.301
2007 Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophrenia Research. 90: 179-85. PMID 17208413 DOI: 10.1016/J.Schres.2006.11.016  0.462
2007 Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 31: 439-42. PMID 17174460 DOI: 10.1016/J.Pnpbp.2006.11.010  0.479
2007 Raisi F, Habibi N, Nasehi AA, Akhondzadeh S. Combination of citalopram and nortriptyline in the treatment of severe major depression: A double-blind, placebo-controlled trial Therapy. 4: 187-192. DOI: 10.2217/14750708.4.2.187  0.442
2007 Mohammadi MR, Akhondzadeh S. Autism spectrum disorders: Etiology and pharmacotherapy Current Drug Therapy. 2: 97-103. DOI: 10.2174/157488507780619095  0.333
2007 Akhondzadeh S. Herbal medicines in the treatment of psychiatric and neurological disorders Low-Cost Approaches to Promote Physical and Mental Health: Theory, Research, and Practice. 119-138. DOI: 10.1007/0-387-36899-X_6  0.386
2006 Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disorders. 8: 485-9. PMID 17042886 DOI: 10.1111/J.1399-5618.2006.00363.X  0.497
2006 Moshiri E, Basti AA, Noorbala AA, Jamshidi AH, Hesameddin Abbasi S, Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 13: 607-11. PMID 16979327 DOI: 10.1016/J.Phymed.2006.08.006  0.498
2006 Akhondzadeh S, Rezaei F, Larijani B, Nejatisafa AA, Kashani L, Abbasi SH. Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophrenia Research. 84: 405-10. PMID 16545544 DOI: 10.1016/J.Schres.2006.02.008  0.374
2006 Akhondzadeh S. Pharmacotherapy of Schizophrenia: The Past, Present and Future Current Drug Therapy. 1: 1-7. DOI: 10.2174/157488506775268461  0.336
2005 Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah-Pour H, Jamshidi AH, Khani M. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytotherapy Research : Ptr. 19: 148-51. PMID 15852492 DOI: 10.1002/Ptr.1647  0.497
2005 Amini H, Aghayan S, Jalili SA, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. Journal of Clinical Pharmacy and Therapeutics. 30: 133-8. PMID 15811165 DOI: 10.1111/J.1365-2710.2004.00585.X  0.486
2005 Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. Journal of Ethnopharmacology. 97: 281-4. PMID 15707766 DOI: 10.1016/J.Jep.2004.11.004  0.481
2005 Akhondzadeh S, Safarcherati A, Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 29: 253-9. PMID 15694232 DOI: 10.1016/J.Pnpbp.2004.11.008  0.479
2005 Akhondzadeh S, Mokhberi K, Amini H, Larijani B, Kashani L, Hashemi L, Nejatisafa AA, Shafaei AR. Is there a relationship between estrogen serum level and symptom severity throughout the menstrual cycle of patients with schizophrenia? Therapy. 2: 745-751. DOI: 10.2217/14750708.2.5.745  0.365
2005 Akhondzadeh S, Milajerdi MR, Amini H, Moin M, Bathaei FS, Kamlipour A. Allopurinol as adjunctive treatment for acute mania in hospitalized bipolar patients Therapy. 2: 739-744. DOI: 10.2217/14750708.2.5.739  0.506
2005 Akhondzadeh S, Mohammadi MR, Momeni F. Passiflora incarnata in the treatment of attention-deficit hyperactivity disorder in children and adolescents Therapy. 2: 609-614. DOI: 10.2217/14750708.2.4.609  0.437
2005 Akhondzadeh S, Mackinejad K, Ahmadi-Abhari SA, Alem ZM. Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia? Therapy. 2: 399-406. DOI: 10.2217/14750708.2.3.399  0.372
2004 Soleimani A, Moayyeri A, Akhondzadeh S, Sadatsafavi M, Tavakoli Shalmani H, Soltanzadeh A. Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: a 17-year experience. Bmc Neurology. 4: 12. PMID 15361260 DOI: 10.1186/1471-2377-4-12  0.363
2004 Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. Bmc Complementary and Alternative Medicine. 4: 12. PMID 15341662 DOI: 10.1186/1472-6882-4-12  0.475
2004 Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. Bmc Psychiatry. 4: 9. PMID 15070418 DOI: 10.1186/1471-244X-4-9  0.467
2004 Akhondzadeh S, Erfani S, Mohammadi MR, Tehrani-Doost M, Amini H, Gudarzi SS, Yasamy MT. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 29: 145-50. PMID 15068403 DOI: 10.1111/J.1365-2710.2004.00546.X  0.47
2004 Mohammadi MR, Kashani L, Akhondzadeh S, Izadian ES, Ohadinia S. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial. Journal of Clinical Pharmacy and Therapeutics. 29: 139-44. PMID 15068402 DOI: 10.1111/J.1365-2710.2004.00545.X  0.436
2004 Mohammadi MR, Ghanizadeh A, Rahgozar M, Noorbala AA, Davidian H, Afzali HM, Naghavi HR, Yazdi SA, Saberi SM, Mesgarpour B, Akhondzadeh S, Alaghebandrad J, Tehranidoost M. Prevalence of obsessive-compulsive disorder in Iran. Bmc Psychiatry. 4: 2. PMID 15018627 DOI: 10.1186/1471-244X-4-2  0.301
2004 Saiiah Bargard M, Assadi SM, Amini H, Saiiah M, Akhondzadeh S, Kamalinejad M. Efficacy of aqueous extract of Echium amoenum L. in the treatment of mild to moderate major depressive disorder: A randomized double blind clinical trial Journal of Medicinal Plants. 3: 61-68+XIX.  0.345
2004 Noorbala AA, Tahmasebi-Pour N, Akhondzadeh S, Khani M, Jamshidi AH. Crocus sativus L. in the treatment of mild to moderate depression: A double-blind, randomised and placebo controlled trial Journal of Medicinal Plants. 3: 31-38+XV.  0.323
2003 Akhondzadeh S, Faraji H, Sadeghi M, Afkham K, Fakhrzadeh H, Kamalipour A. Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression. Journal of Clinical Pharmacy and Therapeutics. 28: 379-84. PMID 14632962 DOI: 10.1046/J.0269-4727.2003.00505.X  0.445
2003 Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L, Raisi F, Kamalipour A. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 1007-12. PMID 14499318 DOI: 10.1016/S0278-5846(03)00161-1  0.461
2003 Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 841-5. PMID 12921918 DOI: 10.1016/S0278-5846(03)00117-9  0.413
2003 Akhondzadeh S. Hydroxyzine may be safe and effective in generalised anxiety disorder. Evidence-Based Mental Health. 6: 91. PMID 12893802 DOI: 10.1136/Ebmh.6.3.91  0.318
2003 Akhondzadeh S, Mohajari H, Reza Mohammadi M, Amini H. Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial. Bmc Psychiatry. 3: 7. PMID 12816549 DOI: 10.1186/1471-244X-3-7  0.505
2003 Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. Journal of Neurology, Neurosurgery, and Psychiatry. 74: 863-6. PMID 12810768 DOI: 10.1136/Jnnp.74.7.863  0.395
2003 Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 28: 53-9. PMID 12605619 DOI: 10.1046/J.1365-2710.2003.00463.X  0.363
2003 Akhondzadeh S, Kashani L, Fotouhi A, Jarvandi S, Mobaseri M, Moin M, Khani M, Jamshidi AH, Baghalian K, Taghizadeh M. Comparison of Lavandula angustifolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 123-7. PMID 12551734 DOI: 10.1016/S0278-5846(02)00342-1  0.491
2002 Akhondzadeh S, Mojtahedzadeh V, Mirsepassi GR, Moin M, Amini-Nooshabadi H, Kamalipour A. Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia. Journal of Clinical Pharmacy and Therapeutics. 27: 453-9. PMID 12472985 DOI: 10.1046/J.1365-2710.2002.00445.X  0.399
2002 Gudarzi SS, Yasamy M, Akhondzadeh S. Cyproheptadine in treatment of autism. European Psychiatry : the Journal of the Association of European Psychiatrists. 17: 230-1. PMID 12231270 DOI: 10.1016/S0924-9338(02)00662-4  0.309
2001 Akhondzadeh S, Kashani L, Mobaseri M, Hosseini SH, Nikzad S, Khani M. Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics. 26: 369-73. PMID 11679027 DOI: 10.1046/J.1365-2710.2001.00366.X  0.443
2001 Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. Journal of Clinical Pharmacy and Therapeutics. 26: 363-7. PMID 11679026 DOI: 10.1046/J.1365-2710.2001.00367.X  0.46
2001 Ahmadi-Abhari SA, Akhondzadeh S, Assadi SM, Shabestari OL, Farzanehgan ZM, Kamlipour A. Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics. 26: 67-71. PMID 11286609 DOI: 10.1046/J.1365-2710.2001.00325.X  0.456
2000 Akhondzadeh S, Ahmadi-Abhari SA, Assadi SM, Shabestari OL, Kashani AR, Farzanehgan ZM. Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal. Journal of Clinical Pharmacy and Therapeutics. 25: 347-53. PMID 11123486 DOI: 10.1046/J.1365-2710.2000.00295.X  0.401
1999 Akhondzadeh S, Emamian ES, Ahmadi-Abhari A, Shabestari O, Dadgarnejad M. Is it time to have another look at lithium maintenance therapy in bipolar disorder? Progress in Neuro-Psychopharmacology & Biological Psychiatry. 23: 1011-7. PMID 10621946 DOI: 10.1016/S0278-5846(99)00056-1  0.364
1999 Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, Amini-Nooshabadi H. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. Journal of Clinical Pharmacy and Therapeutics. 24: 369-74. PMID 10583700 DOI: 10.1046/J.1365-2710.1999.00238.X  0.408
1999 Akhondzadeh S, Mohammadi MR, Amini-Nooshabadi H, Davari-Ashtiani R. Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. Journal of Clinical Pharmacy and Therapeutics. 24: 49-52. PMID 10319907 DOI: 10.1046/J.1365-2710.1999.00197.X  0.436
1998 Noorbala AA, Hosseini SH, Mohammadi MR, Akhondzadeh S. Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 23: 155-9. PMID 9786103  0.412
Show low-probability matches.